Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Phase 1
- Conditions
- Lymphoma, B-Cell
- Interventions
- Biological: CART20
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT02965157
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Tumor Hospital, Beijing, China
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
Phase 2
- Conditions
- Gastric Cancer
- Interventions
- Biological: autologous dendritic cells co-cultured with cytokine-induced killer cells
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT02504229
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Tumor Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath